Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Its primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Its corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of its manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. it has sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
Company profile
Ticker
RGEN
Exchange
Website
CEO
Anthony Hunt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Repligen Sweden AB • Repligen GmbH • Repligen Singapore Pte. Ltd. • Repligen Europe B.V. • Repligen (Shanghai) Biotechnology Co. Ltd. • Repligen Japan LLC • Repligen India Private Limited • Repligen Korea Co., Ltd. • ARTeSYN Biosolutions Holdings Ireland Ltd. • ARTeSYN Biosolutions Ireland Limited ...
IRS number
42729386
RGEN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
24 Mar 23
10-K
2022 FY
Annual report
22 Feb 23
8-K
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
8-K
Repligen Appoints Martin D. Madaus to Board of Directors
9 Feb 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
8-K
Repligen Reports Third Quarter 2022 Financial Results
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
8-K
Repligen Reports Second Quarter 2022 Financial Results
2 Aug 22
8-K
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
1 Jun 22
10-Q
2022 Q1
Quarterly report
27 Apr 22
Transcripts
RGEN
Earnings call transcript
2022 Q3
1 Nov 22
RGEN
Earnings call transcript
2022 Q2
2 Aug 22
RGEN
Earnings call transcript
2022 Q1
27 Apr 22
RGEN
Earnings call transcript
2021 Q4
17 Feb 22
RGEN
Earnings call transcript
2021 Q3
28 Oct 21
RGEN
Earnings call transcript
2021 Q1
27 Jul 21
RGEN
Earnings call transcript
2021 Q1
4 May 21
RGEN
Earnings call transcript
2020 Q4
24 Feb 21
RGEN
Earnings call transcript
2020 Q3
5 Nov 20
RGEN
Earnings call transcript
2020 Q2
31 Jul 20
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 523.46 mm | 523.46 mm | 523.46 mm | 523.46 mm | 523.46 mm | 523.46 mm |
| Cash burn (monthly) | 16.64 mm | 6.70 mm | (no burn) | (no burn) | (no burn) | (no burn) |
| Cash used (since last report) | 46.71 mm | 18.80 mm | n/a | n/a | n/a | n/a |
| Cash remaining | 476.75 mm | 504.66 mm | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 28.7 | 75.4 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 435 |
| Opened positions | 79 |
| Closed positions | 71 |
| Increased positions | 155 |
| Reduced positions | 136 |
| 13F shares | Current |
|---|---|
| Total value | 8.99 tn |
| Total shares | 56.17 mm |
| Total puts | 98.90 k |
| Total calls | 227.60 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 6.12 mm | $1.04 tn |
| Vanguard | 5.21 mm | $881.28 bn |
| T. Rowe Price | 5.07 mm | $858.37 bn |
| Eddleman Roy T | 2.71 mm | $0.00 |
| Sands Capital Management | 1.78 mm | $301.56 bn |
| WCM Investment Management | 1.60 mm | $271.23 bn |
| STT State Street | 1.60 mm | $270.89 bn |
| IVZ Invesco | 1.57 mm | $265.99 bn |
| Brown Capital Management | 1.45 mm | $245.89 bn |
| Artisan Partners Limited Partnership | 1.17 mm | $197.73 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Mar 23 | James Bylund | Common Stock | Payment of exercise | Dispose F | No | No | 188 | 210 | 39.48 k | 17,902 |
| 3 Mar 23 | James Bylund | Common Stock | Grant | Acquire A | No | No | 0 | 625 | 0.00 | 18,112 |
| 3 Mar 23 | Anthony Hunt | Common Stock | Payment of exercise | Dispose F | No | No | 188 | 8,244 | 1.55 mm | 195,307 |
| 3 Mar 23 | Anthony Hunt | Common Stock | Grant | Acquire A | No | No | 0 | 18,584 | 0.00 | 203,551 |
| 3 Mar 23 | Christine Gebski | Common Stock | Payment of exercise | Dispose F | No | No | 188 | 126 | 23.69 k | 32,909 |
| 3 Mar 23 | Christine Gebski | Common Stock | Grant | Acquire A | No | No | 0 | 375 | 0.00 | 33,035 |
| 3 Mar 23 | Ralf Kuriyel | Common Stock | Payment of exercise | Dispose F | No | No | 188 | 1,247 | 234.44 k | 24,266 |
| 3 Mar 23 | Ralf Kuriyel | Common Stock | Grant | Acquire A | No | No | 0 | 3,591 | 0.00 | 25,513 |
| 3 Mar 23 | Jon Snodgres | Common Stock | Payment of exercise | Dispose F | No | No | 188 | 3,674 | 690.71 k | 38,091 |
| 3 Mar 23 | Jon Snodgres | Common Stock | Grant | Acquire A | No | No | 0 | 8,795 | 0.00 | 41,765 |
News
Keybanc Maintains Overweight on Repligen, Lowers Price Target to $240
23 Feb 23
Repligen Expects FY23 Sale Of $760M-$800M Vs. $800.22M Estimate, Adjusted EPS Of $2.61-$2.69 Vs. $2.92 Estimate
22 Feb 23
Repligen Q4 Adjusted EPS $0.68 Beats $0.58 Estimate, Sales $186.76M Beat $184.56M Estimate
22 Feb 23
Earnings Scheduled For February 22, 2023
22 Feb 23
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
30 Jan 23
Press releases
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
14 Mar 23
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
Repligen Appoints Martin D. Madaus to Board of Directors
9 Feb 23
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
8 Feb 23
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23